Content about glucagon

December 6, 2012

The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

DANBURY, Conn. — The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

Biodel announced that it had received orphan drug designation for glucagon to prevent hypoglycemia, or abnormally low blood sugar, in patients with CHI.

November 5, 2012

Whatever dazzling visions science fiction may offer of the widgets of the future, the long, uphill road of technology inevitably leads to the smaller and the simpler.

Whatever dazzling visions science fiction may offer of the widgets of the future, the long, uphill road of technology inevitably leads to the smaller and the simpler. The horse and carriage gave way to the automobile; vacuum tubes gave way to transistors; and computers that took up entire rooms and required intricate climate-control technologies now fit in one’s pocket. 


Technologies used in health care have undergone a similar transition, and much of that has happened in the last few years thanks to the spread of mobile technology. 


September 4, 2012

Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

INDIANPOLIS — Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

The Lilly Glucagon mobile app is an interactive tool designed to teach caregivers how to use severe hypoglycemia treatment Glucagon (1-mg) for injection through simulated practice, thus helping caregivers better understand Glucagon's role in diabetes management. The Lilly Glucagon mobile app includes:

  • Information about severe hypoglycemia and Glucagon;

January 28, 2011

Researchers at the University of Texas Southwestern Medical Center suggested that taking away the actions of a certain hormone can alter Type 1 diabetes into "an asymptomatic, noninsulin-dependent disorder."

DALLAS — Researchers at the University of Texas Southwestern Medical Center suggested that taking away the actions of a certain hormone can alter Type 1 diabetes into "an asymptomatic, noninsulin-dependent disorder."

When testing mice, the researchers found that insulin is not depended on when the body's hormone, glucagon, is suppressed.

December 2, 2010

Oramed Pharmaceuticals, a developer of oral drug delivery solutions, has published an article in the Journal of Diabetes Science and Technology’s November issue describing evaluation of the company’s glucagon-like peptide (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.

JERUSALEM — Oramed Pharmaceuticals, a developer of oral drug delivery solutions, has published an article in the Journal of Diabetes Science and Technology’s November issue describing evaluation of the company’s glucagon-like peptide (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.